<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04663347</url>
  </required_header>
  <id_info>
    <org_study_id>GCT3013-02</org_study_id>
    <nct_id>NCT04663347</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma</brief_title>
  <official_title>A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody®-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genmab</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Genmab</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase 1b/2, open-label, multinational, interventional trial to evaluate the safety,&#xD;
      tolerability, PK, pharmacodynamics/biomarkers, immunogenicity, and preliminary efficacy of&#xD;
      epcoritamab in combination with other standard of care (SOC) agents in subjects with B-NHL.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The following regimens will be investigated:&#xD;
&#xD;
        -  Arm 1: epcoritamab + rituximab, cyclophosphamide, doxorubicin, vincristine, and&#xD;
           prednisone (R-CHOP) in subjects with previously untreated diffuse large B-cell lymphoma&#xD;
           (DLBCL)&#xD;
&#xD;
        -  Arm 2: epcoritamab + rituximab and lenalidomide (R2) in subjects with&#xD;
           relapsed/refractory (R/R) follicular lymphoma (FL)&#xD;
&#xD;
        -  Arm 3: epcoritamab + rituximab and bendamustine (BR) in subjects with previously&#xD;
           untreated FL&#xD;
&#xD;
        -  Arm 4: epcoritamab + rituximab, cytarabine, dexamethasone, and oxaliplatin/ carboplatin&#xD;
           (R-DHAX/C) in subjects with R/R DLBCL eligible for autologous stem cell transplant&#xD;
           (ASCT)&#xD;
&#xD;
        -  Arm 5: epcoritamab + gemcitabine and oxaliplatin (GemOx) in subjects with R/R DLBCL&#xD;
           ineligible for ASCT due to age, performance status (PS), or comorbidity&#xD;
&#xD;
        -  Arm 6: epcoritamab + rituximab and lenalidomide (R2) in subjects with previously&#xD;
           untreated FL&#xD;
&#xD;
        -  Arm 7: epcoritamab maintenance in subjects with FL who achieve CR or PR with SOC&#xD;
           treatment&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 16, 2020</start_date>
  <completion_date type="Anticipated">November 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Escalation Phase - Number of dose-limiting toxicities (DLTs)</measure>
    <time_frame>DLTs are evaluated during the first cycle (28 days) in each cohort</time_frame>
    <description>To evaluate the safety of epcoritamab in combination with other agents</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose Escalation Phase - Number of Adverse Events</measure>
    <time_frame>From first dose up to safety follow-up (60 days after last trial treatment)</time_frame>
    <description>To evaluate the safety of epcoritamab in combination with other agents</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Expansion Part - Preliminary anti-tumor activity</measure>
    <time_frame>Up to approximately 3 years after the last subject's first treatment</time_frame>
    <description>To evaluate the overall response rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics concentration of epcoritamab</measure>
    <time_frame>From start of treatment throughout all treatment cycles (each cycle is 28 days) until LPLV, approximately 3 years</time_frame>
    <description>To evaluate PK parameter - Clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics concentration of epcoritamab</measure>
    <time_frame>From start of treatment throughout all treatment cycles (each cycle is 28 days) until LPLV, approximately 3 years</time_frame>
    <description>To evaluate PK parameter - Volume of distribution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics concentration of epcoritamab</measure>
    <time_frame>From start of treatment throughout all treatment cycles (each cycle is 28 days) until LPLV, approximately 3 years</time_frame>
    <description>To evaluate PK parameter - AUC0-last (Area under the concentration-time curve (AUC) from time zero to last quantifiable sample)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics concentration of epcoritamab</measure>
    <time_frame>From start of treatment throughout all treatment cycles (each cycle is 28 days) until LPLV, approximately 3 years</time_frame>
    <description>To evaluate PK parameter - Area under the concentration-time curve (AUC) from time zero to infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics concentration of epcoritamab</measure>
    <time_frame>From start of treatment throughout all treatment cycles (each cycle is 28 days) until LPLV, approximately 3 years</time_frame>
    <description>To evaluate PK parameter - Cmax (maximum (peak) plasma drug concentration)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics concentration of epcoritamab</measure>
    <time_frame>From start of treatment throughout all treatment cycles (each cycle is 28 days) until LPLV, approximately 3 years</time_frame>
    <description>To evaluatePK parameter - Tmax (time to reach maximum (peak) plasma concentration)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics concentration of epcoritamab</measure>
    <time_frame>From start of treatment throughout all treatment cycles (each cycle is 28 days) until LPLV, approximately 3 years</time_frame>
    <description>To evaluate PK parameters - Predose values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics concentration of epcoritamab</measure>
    <time_frame>From start of treatment throughout all treatment cycles (each cycle is 28 days) until LPLV, approximately 3 years</time_frame>
    <description>To evaluate PK parameters - t½ (elimination half-life)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-drug antibodies (ADAs) to Epcoritamab</measure>
    <time_frame>From start of treatment until end of treatment, approximately 24 months</time_frame>
    <description>To evaluate immunogenicity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>Approximately 3 years after the last subject's first treatment</time_frame>
    <description>To evaluate the preliminary anti-tumor activity of epcoritamab in combination with other agents</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response (TTR)</measure>
    <time_frame>Approximately 3 years after the last subject's first treatment</time_frame>
    <description>To evaluate the preliminary anti-tumor activity of epcoritamab in combination with other agents</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progressive-free survival (PFS)</measure>
    <time_frame>Approximately 3 years after the last subject's first treatment</time_frame>
    <description>To evaluate the preliminary anti-tumor activity of epcoritamab in combination with other agents</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Approximately 3 years after the last subject's first treatment</time_frame>
    <description>To evaluate the preliminary anti-tumor activity of epcoritamab in combination with other agents</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to next anti-lymphoma therapy (TTNT)</measure>
    <time_frame>Approximately 3 years after the last subject's first treatment</time_frame>
    <description>To evaluate the preliminary anti-tumor activity of epcoritamab in combination with other agents</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of minimal residual disease (MRD) negativity</measure>
    <time_frame>Approximately 3 years after the last subject's first treatment</time_frame>
    <description>To evaluate the preliminary anti-tumor activity of epcoritamab in combination with other agents</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of minimal residual disease (MRD) negativity</measure>
    <time_frame>Approximately 3 years after the last subject's first treatment</time_frame>
    <description>To evaluate the preliminary anti-tumor activity of epcoritamab in combination with other agents</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety run-in only: preliminary anti-tumor activity as measured by the overall response rate</measure>
    <time_frame>Approximately 3 years after the last subject's first treatment</time_frame>
    <description>To evaluate the preliminary anti-tumor activity of epcoritamab in combination with other agents</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expansion only: Monitor number and severity of AEs</measure>
    <time_frame>Up to safety follow-up (up to 60days after last dose)</time_frame>
    <description>To evaluate the safety and tolerability of epcoritamab in combination with other agents</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expansion only: Monitor number and severity of changes in laboratory values</measure>
    <time_frame>Up to safety follow-up (up to 60days after last dose)</time_frame>
    <description>To evaluate the safety and tolerability of epcoritamab in combination with other agents</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expansion only: Monitor number of dose interruptions and delays</measure>
    <time_frame>Up to safety follow-up (up to 60days after last dose)</time_frame>
    <description>To evaluate the safety and tolerability of epcoritamab in combination with other agents</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">270</enrollment>
  <condition>Diffuse Large B-Cell Lymphoma</condition>
  <condition>Follicular Lymphoma</condition>
  <arm_group>
    <arm_group_label>Arm 1 - Epcoritamab + R-CHOP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Epcoritamab + R-CHOP in subjects with previously untreated DLBCL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2 - Epcoritamab + R- Lenalidomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Epcoritamab + R- Lenalidomide in subjects with R/R FL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3 - Epcoritamab + BR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Epcoritamab + BR in subjects with previously untreated FL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4 - Epcoritamab + R-DHAX/C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Epcoritamab + R-DHAX/C in subjects with R/R DLBCL Eligible ASCT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 5 - Epcoritamab + GemOx</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Epcoritamab + GemOx in subjects with R/R DLBCL Ineligible ASCT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 6 - Epcoritamab + R- Lenalidomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Epcoritamab + R- Lenalidomide in subjects with previously untreated FL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 7 - Epcoritamab maintenance</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Epcoritamab alone in subjects with FL who achieved a CR or PR after receiving SOC treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone</intervention_name>
    <description>21-day cycles</description>
    <arm_group_label>Arm 1 - Epcoritamab + R-CHOP</arm_group_label>
    <other_name>R-CHOP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rituximab and lenalidomide</intervention_name>
    <description>28-day cycles</description>
    <arm_group_label>Arm 2 - Epcoritamab + R- Lenalidomide</arm_group_label>
    <arm_group_label>Arm 6 - Epcoritamab + R- Lenalidomide</arm_group_label>
    <other_name>R2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rituximab and bendamustine</intervention_name>
    <description>28-day cycles</description>
    <arm_group_label>Arm 3 - Epcoritamab + BR</arm_group_label>
    <other_name>BR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rituximab, cytarabine, dexamethasone, and oxaliplatin/carboplatin</intervention_name>
    <description>21-day cycles</description>
    <arm_group_label>Arm 4 - Epcoritamab + R-DHAX/C</arm_group_label>
    <other_name>R-DHAX/C</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine and oxaliplatin</intervention_name>
    <description>28-day cycles</description>
    <arm_group_label>Arm 5 - Epcoritamab + GemOx</arm_group_label>
    <other_name>GemOx</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Epcoritamab</intervention_name>
    <description>Epcoritamab will be administered in combination with the respective standard of care chemotherapy.</description>
    <arm_group_label>Arm 1 - Epcoritamab + R-CHOP</arm_group_label>
    <arm_group_label>Arm 2 - Epcoritamab + R- Lenalidomide</arm_group_label>
    <arm_group_label>Arm 3 - Epcoritamab + BR</arm_group_label>
    <arm_group_label>Arm 4 - Epcoritamab + R-DHAX/C</arm_group_label>
    <arm_group_label>Arm 5 - Epcoritamab + GemOx</arm_group_label>
    <arm_group_label>Arm 6 - Epcoritamab + R- Lenalidomide</arm_group_label>
    <other_name>GEN3013; DuoBody®-CD3xCD20</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Epcoritamab Maintenance</intervention_name>
    <description>Epcoritamab will be administered alone as maintenance therapy.</description>
    <arm_group_label>Arm 7 - Epcoritamab maintenance</arm_group_label>
    <other_name>GEN3013; DuoBody®-CD3xCD20</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Subject must sign an ICF&#xD;
&#xD;
          2. At least 18 years of age&#xD;
&#xD;
          3. Measurable disease defined as ≥1 measurable nodal lesion (long axis &gt;1.5 cm and short&#xD;
             axis &gt;1.0 cm) or ≥1 measurable extra-nodal lesion (long axis &gt;1.0 cm) on CT or MRI&#xD;
&#xD;
          4. ECOG PS score of 0, 1 or 2&#xD;
&#xD;
          5. Acceptable organ function at screening&#xD;
&#xD;
          6. CD20-positive NHL at most recent representative tumor biopsy&#xD;
&#xD;
          7. If of childbearing potential subject must practicing a highly effective method of&#xD;
             birth control&#xD;
&#xD;
          8. A man who is sexually active with a woman of childbearing potential must agree to use&#xD;
             a barrier method of birth control&#xD;
&#xD;
        Arm 1:&#xD;
&#xD;
          -  Newly Diagnosed Documented DLBCL&#xD;
&#xD;
          -  DLBCL, NOS&#xD;
&#xD;
          -  &quot;double-hit&quot; or &quot;triple-hit&quot; DLBCL&#xD;
&#xD;
          -  FL Grade 3B&#xD;
&#xD;
        Arm 2: R/R FL&#xD;
&#xD;
        Arm 3: Newly diagnosed, previously untreated FL grade 1-3A&#xD;
&#xD;
        Arm 4:&#xD;
&#xD;
          -  Documented DLBCL and eligible for HDT-ASCT&#xD;
&#xD;
          -  DLBCL, NOS&#xD;
&#xD;
          -  &quot;double-hit&quot; or &quot;triple-hit&quot; DLBCL&#xD;
&#xD;
          -  FL Grade 3B&#xD;
&#xD;
        Arm 5:&#xD;
&#xD;
          -  Relapsed Documented DLBCL and ineligible for HDT-ASCT&#xD;
&#xD;
          -  DLBCL, NOS&#xD;
&#xD;
          -  &quot;double-hit&quot; or &quot;triple-hit&quot; DLBCL&#xD;
&#xD;
          -  FL Grade 3B&#xD;
&#xD;
        Arm 6: Newly diagnosed, previously untreated FL grade 1-3A&#xD;
&#xD;
        Arm 7:&#xD;
&#xD;
          -  FL Grade 1-3A&#xD;
&#xD;
          -  If PR or CR per Lugano criteria following first-line or second-line treatment with SOC&#xD;
             regimen, and last dose of SOC within 6 months prior to enrollment.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Chemotherapy, radiation therapy, or major surgery within 4 weeks prior to the first&#xD;
             dose of epcoritamab&#xD;
&#xD;
          2. Any prior treatment with a bispecific antibody targeting CD3 and CD20.&#xD;
&#xD;
          3. Treatment with CAR-T therapy within 30 days prior to first dose of epcoritamab&#xD;
&#xD;
          4. Clinically significant cardiovascular disease&#xD;
&#xD;
          5. Evidence of significant, uncontrolled concomitant diseases that could affect&#xD;
             compliance with the protocol or interpretation of results&#xD;
&#xD;
          6. CNS lymphoma or known CNS involvement by lymphoma at screening as confirmed by MRI/CT&#xD;
             scan of the brain and, if clinically indicated, by lumbar puncture&#xD;
&#xD;
          7. Active positive tests for hepatitis B virus or hepatitis C virus indicating acute or&#xD;
             chronic infection&#xD;
&#xD;
          8. Known history of seropositivity of human immunodeficiency virus (HIV)&#xD;
&#xD;
          9. Suspected active or latent tuberculosis&#xD;
&#xD;
         10. Neuropathy &gt; grade 1&#xD;
&#xD;
         11. Receiving immunostimulatory agent&#xD;
&#xD;
         12. Prior allogeneic HSCT&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Genmab A/S Trial Information</last_name>
    <phone>+45 70202728</phone>
    <email>clinicaltrials@genmab.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>David Geffen School of Medicine at UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Michigan Comprehensive Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>84109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>John Theurer Cancer Center at Hackensack UMC</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering CC</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Levine Cancer Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UMPC Hillman Cancer Center Cancer Pavillion</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Austin Health</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Austin Health</name>
      <address>
        <city>Heidelberg</city>
        <zip>VIC 3084</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Linear Clinical Research Limited</name>
      <address>
        <city>Nedlands</city>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>AZ Sint-Jan</name>
      <address>
        <city>Brugge</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU UCL Namur Site Godinne</name>
      <address>
        <city>Yvoir</city>
        <zip>5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Hradec Kralove</name>
      <address>
        <city>Hradec Králové</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Århus Hospital</name>
      <address>
        <city>Arhus</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vejle Sygehus</name>
      <address>
        <city>Vejle</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tampere University Hospital</name>
      <address>
        <city>Helsinki</city>
        <zip>33520</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>HUS Cancer Center</name>
      <address>
        <city>Lahti</city>
        <zip>15850</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Dijon - Hopital du Bocage</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Gironde</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Claude Huriez - CHRU Lille</name>
      <address>
        <city>Nordausques</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-Louis</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII (Presidio Papa Giovanni XXIII)</name>
      <address>
        <city>Bergamo</city>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fondazione del Piemonte per l Oncologia Istituto di Candiolo IRCCS</name>
      <address>
        <city>Candiolo</city>
        <zip>10060</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istituto Scientifico Romagnolo Per Lo Studio e La Cura Dei Tumori</name>
      <address>
        <city>Meldola</city>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milan</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Amsterdam UMC, Locatie VUMC</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum Groningen (UMCG)</name>
      <address>
        <city>Groningen</city>
        <zip>9713</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Leids Universitair Medisch Centrum</name>
      <address>
        <city>Leiden</city>
        <zip>2333 ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Maastricht University Medical Center</name>
      <address>
        <city>Maastricht</city>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Erasmus Medisch Centrum</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UMC Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oslo Universitetssykehus HF, Radiumhospitalet</name>
      <address>
        <city>Oslo</city>
        <zip>310</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ICO l Hospitalet</name>
      <address>
        <city>Barcelona</city>
        <zip>08908</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>8035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundacion Jimenez Diaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Södra Älvsborgs Sjukhus</name>
      <address>
        <city>Borås</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska Sjukhuset</name>
      <address>
        <city>Göteborg</city>
        <zip>413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Skånes Universitetssjukhus</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Karolinska Universitetssjukhuset</name>
      <address>
        <city>Solna</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Norrlands Universitetssjukhus</name>
      <address>
        <city>Umeå</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Akademiska Sjukhuset</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University College London Hospitals</name>
      <address>
        <city>London</city>
        <zip>NW1 2PG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Freeman Hospital</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <zip>NE7 7D</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Derriford Hospital</name>
      <address>
        <city>Plymouth</city>
        <zip>PL6 8DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 27, 2020</study_first_submitted>
  <study_first_submitted_qc>December 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2020</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

